Mustang Bio Inc Total Assets
Mustang Bio Inc total assets. Based on the latest financial reports, Mustang Bio Inc (MBIO) holds total assets worth $15.61 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Mustang Bio Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Mustang Bio Inc (2016–2025)
Total assets of Mustang Bio Inc from 2016 to 2025. This chart illustrates how Mustang Bio Inc's total assets have evolved over time, based on quarterly financial data. See MBIO stock price for real-time trading data and today's change.
Mustang Bio Inc - Asset Composition Analysis
Mustang Bio Inc Total Assets Breakdown (December 2025)
Mustang Bio Inc total assets breakdown as of December 2025. Mustang Bio Inc's total assets of $15.61 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.1% |
| Accounts Receivable | $217.00K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Mustang Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Mustang Bio Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mustang Bio Inc's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 98.1% of total assets in 2025, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
Mustang Bio Inc Competitors by Total Assets
Key competitors of Mustang Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Mustang Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 1.30 | 11.66 |
| Quick Ratio | 1.97 | 1.30 | 11.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.70 Million | $3.04 Million | $111.49 Million |
Mustang Bio Inc - Advanced Valuation Insights
This section examines the relationship between Mustang Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.55 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 89.0% |
| Total Assets | $17.59 Million |
| Market Capitalization | $2.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mustang Bio Inc's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Mustang Bio Inc's assets grew by 89.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mustang Bio Inc (2016–2025)
The table below shows the annual total assets of Mustang Bio Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $17.59 Million | +89.01% |
| 2024-12-31 | $9.31 Million | -47.54% |
| 2023-12-31 | $17.74 Million | -80.80% |
| 2022-12-31 | $92.42 Million | -26.16% |
| 2021-12-31 | $125.17 Million | +13.89% |
| 2020-12-31 | $109.90 Million | +49.64% |
| 2019-12-31 | $73.44 Million | +71.79% |
| 2018-12-31 | $42.75 Million | -32.66% |
| 2017-12-31 | $63.49 Million | +130.89% |
| 2016-12-31 | $27.50 Million | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more